Developer docs
API playgroundTry for free, no card

Search company profiles

Simbec-Orion

Full company profile

uuid00097si

Namestring
Simbec-Orion
Legal namestring
Simbec-Orion Group Limited
Websiteurl
simbecorion.com
Company typeenum
Private
Founded yearint
1976
Descriptiontext

Simbec-Orion is a privately-held full-service Contract Research Organization (CRO) founded in 1976 and headquartered in Merthyr Tydfil, United Kingdom, operating across more than eleven office locations globally, including the UK, France, Germany, Hungary, Netherlands, Poland, Australia, and the United States. The company delivers clinical trial management services for small to mid-size biotech and pharmaceutical drug developers, with a particular therapeutic focus on oncology (including rare oncology), rare and orphan diseases, respiratory therapeutics, CNS indications, and addiction research. Its named customers include KalVista Pharmaceuticals, Oxford Cannabinoid Technologies, Mission Therapeutics, Molecure, AL-S Pharma, ImmuPharma, Exvastat, and Cardiff University, with the client base spread across Europe, the United States, Canada, Australia, New Zealand, and Asia-Pacific.

The company's service portfolio spans the full clinical development lifecycle: early-stage consultancy, First-in-Human and Phase Ib/2a studies, Phase II and Phase III trials, pharmacovigilance, regulatory affairs, medical writing, bioanalytical and central laboratory services, SMO services, and post-market studies. Core infrastructure is anchored by an MHRA-accredited 58-bed Phase I Clinical Pharmacology Unit in Merthyr Tydfil with onsite pharmacy and central laboratory, complemented by an in-house gamma scintigraphy camera operated via a 25-year collaboration with Cardiff Scintigraphics, and bioanalytical capability including Ella ELISA analyzers from ProteinSimple. Technology infrastructure combines proprietary and partner platforms: ClinSpark EDC (launched December 2024) purpose-built for Phase I, and Veeva Vault systems (CTMS, eTMF, and Quality Suite) for trial and quality management. AI capability is delivered through the biotx.ai strategic partnership for causal modeling aimed at de-risking Phase II efficacy predictions.

Simbec-Orion operates as a professional services business on custom project-based contracts to biotech and pharma customers; pricing is not publicly disclosed. The legal structure is Simbec-Orion Group Limited with wholly-owned operating subsidiaries across multiple jurisdictions (Simbec Research Ltd, Orion Clinical Services Ltd, Orion Clinical Services Inc, Orion Santé Sarl, Simbec-Orion (NL) B.V., Orion Clinical Services Hungary Kft, Orion Clinical Services GmbH, Simbec-Orion (POL) sp. z o.o, and Orion Clinical Services (Australia) Pty Limited). Distribution is direct via enterprise field sales, with operational reach extended to 34 countries through the February 2025 Avance Clinical partnership. Marketing is conducted through educational content (white papers, webinars, case studies, clinical trial publications), industry conference participation (BIO International, ASCO, World Orphan Drug Congress, BioWales), and LinkedIn, with the company recognized as 2019 European Lifestars "CRO of the Year."

Short descriptiontext

Simbec-Orion is a UK-based, privately-held full-service Contract Research Organization delivering clinical trial management services from First-in-Human through Phase III, with specialty focus on oncology and rare diseases. The company serves small and mid-size biotech and pharmaceutical developers globally across 34 countries through direct enterprise sales and an MHRA-accredited Phase I unit.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersMerthyr Tydfil, United Kingdom
HQ citystring
Merthyr Tydfil
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices11 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial management, contract research organization, early phase clinical studies, central laboratory services, regulatory affairs consulting
Industry4 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Medical and Diagnostic Laboratories6215
  • Other Scientific and Technical Consulting Services54169
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Research Services (Contract Research Organization)
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model8 records
1Clinical Trial Management Services
TypeProfessional Services
Description

Full-service clinical development solutions covering Phase I through Phase III and post-market studies. Services include clinical trial management, biometrics, site management and monitoring, and IMP management

simbecorion.com
2Clinical Pharmacology Services
TypeProfessional Services
Description

Purpose-built clinical pharmacology unit conducting all types of studies including First-in-Human, PK, food effect, drug-drug interaction studies. 90% of work with Investigational Medicinal Products

simbecorion.com
3Central Laboratory Services
TypeProfessional Services
Description

Bioanalytical laboratory services, routine safety testing, immunoassays with on-site capabilities for rapid turnaround of sample analysis including safety analysis, biomarkers, and drug concentration analysis

simbecorion.com
4Regulatory Affairs
TypeProfessional Services
Description

Regulatory affairs consulting and submission services including ethics and CTA submissions

simbecorion.com
5Clinical & Medical Writing
TypeProfessional Services
Description

Medical and clinical writing services for study documentation and regulatory submissions

simbecorion.com
6Scintigraphy Services
TypeProfessional Services
Description

Specialized gamma scintigraphy imaging services for respiratory therapeutics research, conducted in partnership with Cardiff Scintigraphics

simbecorion.com
7Pharmacovigilance
TypeProfessional Services
Description

Drug safety monitoring and pharmacovigilance services

simbecorion.com
8SMO Services
TypeProfessional Services
Description

Site Management Organization services for site-level clinical trial support

simbecorion.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Simbec-Orion is a full-service Contract Research Organisation (CRO) that manages clinical trials end-to-end for small and mid-sized biotech and pharmaceutical sponsors, covering Phase I (including First-in-Human, PK, food effect, and drug-drug interaction studies) through Phase III and post-market studies from its MHRA-accredited 58-bed Phase I Clinical Pharmacology Unit. It sells complementary services including central laboratory/bioanalytical testing, scintigraphy imaging, pharmacovigilance, regulatory affairs and submissions, clinical and medical writing, biometric services, site management and monitoring, IMP management, and SMO services, with deep specialization in oncology, rare and orphan diseases, respiratory, and CNS therapeutic areas.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Delivered Phase II results for KVD900 demonstrating statistically and clinically significant responses across all endpoints
+2 more records
Product overview1 text field

Simbec-Orion is a full-service Contract Research Organisation (CRO) offering a comprehensive portfolio of clinical development solutions from early phase (Phase I) through Phase III and post-market studies. The company operates as a single unified platform combining clinical trial management, laboratory services, clinical pharmacology, regulatory affairs, and specialized therapeutic expertise. Key service modules include Clinical Trial Management Services (encompassing Phase I, II, III, site management, IMP management, and biometrics), Central Laboratory Services (bioanalytical, routine safety testing, immunoassays), Clinical Pharmacology, Scintigraphy, Pharmacovigilance, Regulatory Affairs, and Clinical & Medical Writing. The company specializes in oncology and rare disease therapeutic areas, complemented by AI-powered causal modeling capabilities through its biotx.ai partnership. Technology infrastructure includes ClinSpark® electronic data capture platform and Veeva Vault systems (CTMS, eTMF, Quality Suite).

Product and service12 records
1Clinical Trial Management Services
CategoryClinical Trial Management
Description

Full-service clinical trial management covering Phase I through Phase III and post-market studies, including site management and monitoring, IMP management, and biometric services. Targeted at biotech and pharmaceutical sponsors.

2Central Laboratory Services
CategoryLaboratory Services
Description

Comprehensive laboratory support including bioanalytical services, routine safety testing, and immunoassays for clinical sample analysis. Includes an on-site bioanalytical laboratory for safety, biomarker, and drug concentration analysis. Targeted at clinical trial sponsors.

3Clinical Pharmacology
CategoryClinical Pharmacology / Phase I
Description

Full-service clinical pharmacology unit conducting First-in-Human studies, Phase Ib/2a proof of concept, PK/food effect/drug-drug interaction studies, and patient cohort trials at an MHRA-accredited facility with 58-bed capacity. Targeted at biotech and pharmaceutical sponsors needing early-phase development support.

4Scintigraphy Services
CategorySpecialized Imaging Services
Description

Gamma scintigraphy imaging services for respiratory therapeutics research, using an in-house gamma scintigraphy camera with over 25 years of experience in scintigraphy trials. Provided in partnership with Cardiff Scintigraphics. Targeted at respiratory drug developers.

5Pharmacovigilance
CategoryDrug Safety / Pharmacovigilance
Description

Drug safety monitoring and pharmacovigilance services provided throughout the clinical trial process. Targeted at biotech and pharmaceutical sponsors requiring continuous safety oversight.

6Regulatory Affairs
CategoryRegulatory Services
Description

Regulatory strategy and submission services including ethics and Clinical Trial Application (CTA) submissions, leveraging early regulatory engagement through Scientific Advice. Targeted at biotech and pharmaceutical sponsors needing regulatory pathway support.

7Clinical & Medical Writing
CategoryMedical Writing
Description

Professional medical and clinical writing services for study documentation and regulatory submissions. Targeted at biotech and pharmaceutical sponsors.

8Data Quality, Security & Compliance
CategoryData Management
Description

Data management services ensuring quality, security, and regulatory compliance for clinical trial data, integrated with Veeva Vault CTMS and eTMF. Targeted at clinical trial sponsors needing end-to-end data oversight.

9SMO Services
CategorySite Management Organization
Description

Site Management Organization services providing site coordination, management, and monitoring support for clinical trial sites. Targeted at biotech and pharmaceutical sponsors needing site-level execution support.

10Early Stage Consultancy Services
CategoryConsulting Services
Description

Early-stage drug development advisory and consultancy services including Scientific Advice consultation. Delivered with support from an independent Drug Development Advisory Board including former MHRA experts. Targeted at biotech and pharmaceutical sponsors planning early development programs.

11AI Causal Modeling Service
CategoryAI-Enabled Clinical Trial Design
Description

AI-enabled causal modeling service through the biotx.ai partnership that processes nonclinical data to predict Phase II efficacy and identify comprehensive biomarker endpoints for clinical development. Targeted at biotech and pharmaceutical sponsors seeking to de-risk early-stage drug development.

12ClinSpark® Electronic Data Capture Platform
CategoryElectronic Data Capture / Clinical Trial Technology
Description

State-of-the-art electronic data capture (EDC) platform purpose-built to optimize Phase I studies, integrated into Simbec-Orion's clinical technology stack. Targeted at clinical trial sponsors running Phase I trials.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-26
Description

Strategic partnership agreement forming collaborative framework between two full-service CROs to deliver globally integrated clinical trial solutions. Partnership enables Simbec-Orion to expand into Australia and Asia-Pacific while extending Avance Clinical's capabilities in Europe and UK. Combined operations span 34 countries across Europe, US, Canada, Australia, New Zealand, and Asia. Both CROs operate as unified entity to execute Phase I through Phase III trials.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-10-26
Description

Strategic partnership to bring AI-powered insights and predictive models to support data-driven clinical trial design. biotx.ai provides AI-enabled causal modeling for drug development that is closer to human systems than traditional animal models, offering more accurate predictions for efficacy in Phase II. Partnership helps de-risk early-stage drug development.

Strategic tierCoreTypeTechnology or Integration
Description

Partnership for Veeva Vault clinical applications including Vault CTMS and Vault eTMF for end-to-end clinical trial data and document management, and Veeva Vault Quality Suite for quality management. Alison Hughes recognized as Veeva Hero for implementation leadership. Systems enable digital execution and quality oversight.

4ImmuPharma
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership for international Phase III trial of Lupuzor, an in-development treatment for Lupus affecting approximately 5 million people worldwide. Trial involves pharmacokinetic studies following FDA approval.

simbecorion.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Trusted to conduct milestone first-in-human Phase I clinical trial of lead compound OCT461201 for Postherpetic Neuralgia (PHN) and Irritable Bowel Syndrome. Represents significant milestone for Oxford Cannabinoid's clinical development program.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Agreement signed July 2023 to conduct Phase II clinical trial for Molecure's lead molecule OATD-01 in pulmonary sarcoidosis patients, taking important step in development program.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Successful delivery of Phase I clinical trial for MTX652 (lead DUB program), achieving milestone showing drug was well tolerated and safe up to single dose of 200mg and multiple doses of 100mg once daily for 14 days.

8AL-S Pharma
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Supporting Phase II ALS Study (AP-101) in Amyotrophic Lateral Sclerosis, a rare progressive neurodegenerative disease. AP-101 is monoclonal antibody administered by intravenous infusion targeting misfolded SOD1.

simbecorion.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Phase II clinical trial for KVD900 as oral on-demand treatment for Hereditary Angioedema attacks, demonstrating statistically and clinically significant responses across all endpoints with reduced rescue medication use.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration on COVID-19 trial studying imatinib in treatment of COVID-19 associated ARDS. Exvastat won 3.6 million euro grant from Innovative Medicines Initiative for reformulation and study.

11Cardiff Scintigraphics
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Over 25-year collaboration with Cardiff Scintigraphics for scintigraphy trials on asthmatic and COPD patients using in-house gamma scintigraphy camera.

simbecorion.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership for EEG assessments in Phase I unit for schizophrenia cognitive impairment trial, combining neuroscience, neurology and psychology expertise with electro-diagnostic technology.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Neuroimaging conducted at CUBRIC for Phase I trial with Cardiff University's Medicines Discovery Institute, supporting South Wales drug development network.

14Oncodistinct Network
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Charter agreement strengthening relationships between Simbec-Orion and Oncodistinct network of oncology sites for partnership in operations and scientific expertise in design and conduct of early phase oncology studies.

simbecorion.com
Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Public mid-size CRO (NASDAQ: MEDP) renowned for its biotech-focused operating model and lean scientific staffing. Closest publicly traded analog and benchmark on unit economics for a biotech-focused CRO of Simbec-Orion's profile.

TypeDirect peer
Description

Mid-size, full-service CRO with comparable therapeutic specialization (rare disease, oncology, CNS) and similar biotech/mid-pharma customer mix. Operates as a private mid-tier alternative to mega-CROs, directly contesting Simbec-Orion for the same Phase II/III contracts.

TypeDirect peer
Description

Mid-size full-service CRO historically focused on small/mid-size biotech with strong rare disease, oncology, and pediatric credentials. Highly comparable on therapeutic focus, customer segment, and project-based clinical delivery model.

TypeDirect peer
Description

Private mid-size CRO with therapeutic breadth across oncology, rare disease, and infectious disease, serving small-to-mid biotech. Direct competitor for the same Phase II-III RFPs and similar clinical technology stack.

TypeBroad incumbent
Description

Global CRO/pharma services leader with comprehensive Phase I-IV capabilities. Simbec-Orion competes for the small/mid-biotech subset of contracts where customers seek a more agile partner than the mega-CROs.

TypeBroad incumbent
Description

Large preclinical/clinical services provider; its Discovery & Safety Assessment segment plus early-phase clinical franchise directly competes with Simbec-Orion's Phase I unit and central lab services for biotech accounts.

TypeDirect peer
Description

Australia-headquartered full-service mid-size CRO that signed a strategic partnership with Simbec-Orion in February 2025 to deliver unified Phase I-IV services across 34 countries. Most directly comparable peer given similar size, biotech focus, and formalized cross-region alliance.

TypeOthers
Description

Clinical trial technology and endpoint services provider; relevant comparator because Simbec-Orion's ClinSpark EDC, Veeva Vault integration, and Ella ELISA platform mix clinical services with technology tooling in similar fashion.

9INC Research (Syneos Health legacy)
TypeBroad incumbent
Description

Large global CRO formed from the merger of INC Research and inVentiv; provides end-to-end clinical services that overlap Simbec-Orion's offerings but at greater scale and broader therapeutic coverage, including late-phase and post-marketing.

TypeBroad incumbent
Description

Top-tier global CRO offering Phase I-IV and post-approval services. Overlaps with Simbec-Orion's biotech/biopharma customer segment but at much larger scale and broader geographic footprint.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration6 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Simbec-Orion

Clinical Research Services (Contract Research Organization)simbecorion.com

Simbec-Orion is a UK-based, privately-held full-service Contract Research Organization delivering clinical trial management services from First-in-Human through Phase III, with specialty focus on oncology and rare diseases. The company serves small and mid-size biotech and pharmaceutical developers globally across 34 countries through direct enterprise sales and an MHRA-accredited Phase I unit.

What Simbec-Orion does

Simbec-Orion is a privately-held full-service Contract Research Organization (CRO) founded in 1976 and headquartered in Merthyr Tydfil, United Kingdom, operating across more than eleven office locations globally, including the UK, France, Germany, Hungary, Netherlands, Poland, Australia, and the United States. The company delivers clinical trial management services for small to mid-size biotech and pharmaceutical drug developers, with a particular therapeutic focus on oncology (including rare oncology), rare and orphan diseases, respiratory therapeutics, CNS indications, and addiction research. Its named customers include KalVista Pharmaceuticals, Oxford Cannabinoid Technologies, Mission Therapeutics, Molecure, AL-S Pharma, ImmuPharma, Exvastat, and Cardiff University, with the client base spread across Europe, the United States, Canada, Australia, New Zealand, and Asia-Pacific.

The company's service portfolio spans the full clinical development lifecycle: early-stage consultancy, First-in-Human and Phase Ib/2a studies, Phase II and Phase III trials, pharmacovigilance, regulatory affairs, medical writing, bioanalytical and central laboratory services, SMO services, and post-market studies. Core infrastructure is anchored by an MHRA-accredited 58-bed Phase I Clinical Pharmacology Unit in Merthyr Tydfil with onsite pharmacy and central laboratory, complemented by an in-house gamma scintigraphy camera operated via a 25-year collaboration with Cardiff Scintigraphics, and bioanalytical capability including Ella ELISA analyzers from ProteinSimple. Technology infrastructure combines proprietary and partner platforms: ClinSpark EDC (launched December 2024) purpose-built for Phase I, and Veeva Vault systems (CTMS, eTMF, and Quality Suite) for trial and quality management. AI capability is delivered through the biotx.ai strategic partnership for causal modeling aimed at de-risking Phase II efficacy predictions.

Simbec-Orion operates as a professional services business on custom project-based contracts to biotech and pharma customers; pricing is not publicly disclosed. The legal structure is Simbec-Orion Group Limited with wholly-owned operating subsidiaries across multiple jurisdictions (Simbec Research Ltd, Orion Clinical Services Ltd, Orion Clinical Services Inc, Orion Santé Sarl, Simbec-Orion (NL) B.V., Orion Clinical Services Hungary Kft, Orion Clinical Services GmbH, Simbec-Orion (POL) sp. z o.o, and Orion Clinical Services (Australia) Pty Limited). Distribution is direct via enterprise field sales, with operational reach extended to 34 countries through the February 2025 Avance Clinical partnership. Marketing is conducted through educational content (white papers, webinars, case studies, clinical trial publications), industry conference participation (BIO International, ASCO, World Orphan Drug Congress, BioWales), and LinkedIn, with the company recognized as 2019 European Lifestars "CRO of the Year."

Simbec-Orion firmographics

Firmographics
Name
Simbec-Orion
Legal name
Simbec-Orion Group Limited
Website
https://simbecorion.com
Company type
Private
Founded year
1976
Operating status
Operating
Headcount range
251–500 employees
Short description
Simbec-Orion is a UK-based, privately-held full-service Contract Research Organization delivering clinical trial management services from First-in-Human through Phase III, with specialty focus on oncology and rare diseases. The company serves small and mid-size biotech and pharmaceutical developers globally across 34 countries through direct enterprise sales and an MHRA-accredited Phase I unit.
Ownership category
akta.pro rank

Simbec-Orion industry classification

Industry
Product category
Clinical Research Services (Contract Research Organization)
NAICS
Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215), Other Scientific and Technical Consulting Services (54169)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs

Keywords

  • Clinical trial management
  • Contract research organization
  • Early phase clinical studies
  • Central laboratory services
  • Regulatory affairs consulting

Where Simbec-Orion is headquartered

Location

Headquarters

HQ city
Merthyr Tydfil
HQ country
United Kingdom
HQ region
Europe

Offices11 records

Markets served

Simbec-Orion business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Clinical Trial Management Services: Full-service clinical development solutions covering Phase I through Phase III and post-market studies. Services include clinical trial management, biometrics, site management and monitoring, and IMP management
  2. Clinical Pharmacology Services: Purpose-built clinical pharmacology unit conducting all types of studies including First-in-Human, PK, food effect, drug-drug interaction studies. 90% of work with Investigational Medicinal Products
  3. Central Laboratory Services: Bioanalytical laboratory services, routine safety testing, immunoassays with on-site capabilities for rapid turnaround of sample analysis including safety analysis, biomarkers, and drug concentration analysis
  4. Regulatory Affairs: Regulatory affairs consulting and submission services including ethics and CTA submissions
  5. Clinical & Medical Writing: Medical and clinical writing services for study documentation and regulatory submissions
  6. Scintigraphy Services: Specialized gamma scintigraphy imaging services for respiratory therapeutics research, conducted in partnership with Cardiff Scintigraphics
  7. Pharmacovigilance: Drug safety monitoring and pharmacovigilance services
  8. SMO Services: Site Management Organization services for site-level clinical trial support

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Simbec-Orion product offering

Product offering

Core offering

Simbec-Orion is a full-service Contract Research Organisation (CRO) that manages clinical trials end-to-end for small and mid-sized biotech and pharmaceutical sponsors, covering Phase I (including First-in-Human, PK, food effect, and drug-drug interaction studies) through Phase III and post-market studies from its MHRA-accredited 58-bed Phase I Clinical Pharmacology Unit. It sells complementary services including central laboratory/bioanalytical testing, scintigraphy imaging, pharmacovigilance, regulatory affairs and submissions, clinical and medical writing, biometric services, site management and monitoring, IMP management, and SMO services, with deep specialization in oncology, rare and orphan diseases, respiratory, and CNS therapeutic areas.

Product overview

Simbec-Orion is a full-service Contract Research Organisation (CRO) offering a comprehensive portfolio of clinical development solutions from early phase (Phase I) through Phase III and post-market studies. The company operates as a single unified platform combining clinical trial management, laboratory services, clinical pharmacology, regulatory affairs, and specialized therapeutic expertise. Key service modules include Clinical Trial Management Services (encompassing Phase I, II, III, site management, IMP management, and biometrics), Central Laboratory Services (bioanalytical, routine safety testing, immunoassays), Clinical Pharmacology, Scintigraphy, Pharmacovigilance, Regulatory Affairs, and Clinical & Medical Writing. The company specializes in oncology and rare disease therapeutic areas, complemented by AI-powered causal modeling capabilities through its biotx.ai partnership. Technology infrastructure includes ClinSpark® electronic data capture platform and Veeva Vault systems (CTMS, eTMF, Quality Suite).

Differentiator

Problem solved

Functional benefit

Products and services

  • Clinical Trial Management Services Full-service clinical trial management covering Phase I through Phase III and post-market studies, including site management and monitoring, IMP management, and biometric services. Targeted at biotech and pharmaceutical sponsors.
  • Central Laboratory Services Comprehensive laboratory support including bioanalytical services, routine safety testing, and immunoassays for clinical sample analysis. Includes an on-site bioanalytical laboratory for safety, biomarker, and drug concentration analysis. Targeted at clinical trial sponsors.
  • Clinical Pharmacology Full-service clinical pharmacology unit conducting First-in-Human studies, Phase Ib/2a proof of concept, PK/food effect/drug-drug interaction studies, and patient cohort trials at an MHRA-accredited facility with 58-bed capacity. Targeted at biotech and pharmaceutical sponsors needing early-phase development support.
  • Scintigraphy Services Gamma scintigraphy imaging services for respiratory therapeutics research, using an in-house gamma scintigraphy camera with over 25 years of experience in scintigraphy trials. Provided in partnership with Cardiff Scintigraphics. Targeted at respiratory drug developers.
  • Pharmacovigilance Drug safety monitoring and pharmacovigilance services provided throughout the clinical trial process. Targeted at biotech and pharmaceutical sponsors requiring continuous safety oversight.
  • Regulatory Affairs Regulatory strategy and submission services including ethics and Clinical Trial Application (CTA) submissions, leveraging early regulatory engagement through Scientific Advice. Targeted at biotech and pharmaceutical sponsors needing regulatory pathway support.
  • Clinical & Medical Writing Professional medical and clinical writing services for study documentation and regulatory submissions. Targeted at biotech and pharmaceutical sponsors.
  • Data Quality, Security & Compliance Data management services ensuring quality, security, and regulatory compliance for clinical trial data, integrated with Veeva Vault CTMS and eTMF. Targeted at clinical trial sponsors needing end-to-end data oversight.
  • SMO Services Site Management Organization services providing site coordination, management, and monitoring support for clinical trial sites. Targeted at biotech and pharmaceutical sponsors needing site-level execution support.
  • Early Stage Consultancy Services Early-stage drug development advisory and consultancy services including Scientific Advice consultation. Delivered with support from an independent Drug Development Advisory Board including former MHRA experts. Targeted at biotech and pharmaceutical sponsors planning early development programs.
  • AI Causal Modeling Service AI-enabled causal modeling service through the biotx.ai partnership that processes nonclinical data to predict Phase II efficacy and identify comprehensive biomarker endpoints for clinical development. Targeted at biotech and pharmaceutical sponsors seeking to de-risk early-stage drug development.
  • ClinSpark® Electronic Data Capture Platform State-of-the-art electronic data capture (EDC) platform purpose-built to optimize Phase I studies, integrated into Simbec-Orion's clinical technology stack. Targeted at clinical trial sponsors running Phase I trials.

Quantifiable outcome

  • Delivered Phase II results for KVD900 demonstrating statistically and clinically significant responses across all endpoints
  • +2 more outcomes

Companies that use Simbec-Orion

Customer profile

Named customers9 records

Segments4 records

Ideal customer profiles4 records

Simbec-Orion technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability3 records

Feature7 records

Simbec-Orion partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered core and minor.

  • Avance ClinicalcoreStrategic or Co-development Partner · 26 February 2025Strategic partnership agreement forming collaborative framework between two full-service CROs to deliver globally integrated clinical trial solutions. Partnership enables Simbec-Orion to expand into Australia and Asia-Pacific while extending Avance Clinical's capabilities in Europe and UK. Combined operations span 34 countries across Europe, US, Canada, Australia, New Zealand, and Asia. Both CROs operate as unified entity to execute Phase I through Phase III trials.
  • biotx.aicoreTechnology or Integration · 26 October 2023Strategic partnership to bring AI-powered insights and predictive models to support data-driven clinical trial design. biotx.ai provides AI-enabled causal modeling for drug development that is closer to human systems than traditional animal models, offering more accurate predictions for efficacy in Phase II. Partnership helps de-risk early-stage drug development.
  • Veeva SystemscoreTechnology or IntegrationPartnership for Veeva Vault clinical applications including Vault CTMS and Vault eTMF for end-to-end clinical trial data and document management, and Veeva Vault Quality Suite for quality management. Alison Hughes recognized as Veeva Hero for implementation leadership. Systems enable digital execution and quality oversight.
  • ImmuPharmacoreStrategic or Co-development PartnerPartnership for international Phase III trial of Lupuzor, an in-development treatment for Lupus affecting approximately 5 million people worldwide. Trial involves pharmacokinetic studies following FDA approval.
  • Oxford Cannabinoid TechnologiescoreStrategic or Co-development PartnerTrusted to conduct milestone first-in-human Phase I clinical trial of lead compound OCT461201 for Postherpetic Neuralgia (PHN) and Irritable Bowel Syndrome. Represents significant milestone for Oxford Cannabinoid's clinical development program.
  • MolecurecoreStrategic or Co-development PartnerAgreement signed July 2023 to conduct Phase II clinical trial for Molecure's lead molecule OATD-01 in pulmonary sarcoidosis patients, taking important step in development program.
  • Mission TherapeuticscoreStrategic or Co-development PartnerSuccessful delivery of Phase I clinical trial for MTX652 (lead DUB program), achieving milestone showing drug was well tolerated and safe up to single dose of 200mg and multiple doses of 100mg once daily for 14 days.
  • AL-S PharmacoreStrategic or Co-development PartnerSupporting Phase II ALS Study (AP-101) in Amyotrophic Lateral Sclerosis, a rare progressive neurodegenerative disease. AP-101 is monoclonal antibody administered by intravenous infusion targeting misfolded SOD1.
  • KalVista PharmaceuticalscoreStrategic or Co-development PartnerPhase II clinical trial for KVD900 as oral on-demand treatment for Hereditary Angioedema attacks, demonstrating statistically and clinically significant responses across all endpoints with reduced rescue medication use.
  • ExvastatminorStrategic or Co-development PartnerCollaboration on COVID-19 trial studying imatinib in treatment of COVID-19 associated ARDS. Exvastat won 3.6 million euro grant from Innovative Medicines Initiative for reformulation and study.
  • Cardiff ScintigraphicscoreStrategic or Co-development PartnerOver 25-year collaboration with Cardiff Scintigraphics for scintigraphy trials on asthmatic and COPD patients using in-house gamma scintigraphy camera.
  • The Science BehindminorStrategic or Co-development PartnerPartnership for EEG assessments in Phase I unit for schizophrenia cognitive impairment trial, combining neuroscience, neurology and psychology expertise with electro-diagnostic technology.
  • Cardiff University Brain Research Imaging Centre (CUBRIC)minorStrategic or Co-development PartnerNeuroimaging conducted at CUBRIC for Phase I trial with Cardiff University's Medicines Discovery Institute, supporting South Wales drug development network.
  • Oncodistinct NetworkcoreStrategic or Co-development PartnerCharter agreement strengthening relationships between Simbec-Orion and Oncodistinct network of oncology sites for partnership in operations and scientific expertise in design and conduct of early phase oncology studies.

Scale indicators6 records

Recent moves12 records

Expansion highlights7 records

Simbec-Orion competitors and assessment

Company assessment

Direct peers

  • Medpace Holdings: Public mid-size CRO (NASDAQ: MEDP) renowned for its biotech-focused operating model and lean scientific staffing. Closest publicly traded analog and benchmark on unit economics for a biotech-focused CRO of Simbec-Orion's profile.
  • Worldwide Clinical Trials: Mid-size, full-service CRO with comparable therapeutic specialization (rare disease, oncology, CNS) and similar biotech/mid-pharma customer mix. Operates as a private mid-tier alternative to mega-CROs, directly contesting Simbec-Orion for the same Phase II/III contracts.
  • Premier Research: Mid-size full-service CRO historically focused on small/mid-size biotech with strong rare disease, oncology, and pediatric credentials. Highly comparable on therapeutic focus, customer segment, and project-based clinical delivery model.
  • Clinipace Worldwide: Private mid-size CRO with therapeutic breadth across oncology, rare disease, and infectious disease, serving small-to-mid biotech. Direct competitor for the same Phase II-III RFPs and similar clinical technology stack.
  • Avance Clinical: Australia-headquartered full-service mid-size CRO that signed a strategic partnership with Simbec-Orion in February 2025 to deliver unified Phase I-IV services across 34 countries. Most directly comparable peer given similar size, biotech focus, and formalized cross-region alliance.

Broad incumbents

  • IQVIA: Global CRO/pharma services leader with comprehensive Phase I-IV capabilities. Simbec-Orion competes for the small/mid-biotech subset of contracts where customers seek a more agile partner than the mega-CROs.
  • Charles River Laboratories: Large preclinical/clinical services provider; its Discovery & Safety Assessment segment plus early-phase clinical franchise directly competes with Simbec-Orion's Phase I unit and central lab services for biotech accounts.
  • INC Research (Syneos Health legacy): Large global CRO formed from the merger of INC Research and inVentiv; provides end-to-end clinical services that overlap Simbec-Orion's offerings but at greater scale and broader therapeutic coverage, including late-phase and post-marketing.
  • ICON plc: Top-tier global CRO offering Phase I-IV and post-approval services. Overlaps with Simbec-Orion's biotech/biopharma customer segment but at much larger scale and broader geographic footprint.

Others

  • ERT (Clario): Clinical trial technology and endpoint services provider; relevant comparator because Simbec-Orion's ClinSpark EDC, Veeva Vault integration, and Ella ELISA platform mix clinical services with technology tooling in similar fashion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Simbec-Orion social profiles

Digital presence

Simbec-Orion compliance and trust

Trust signal

Compliance2 records

Simbec-Orion financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Simbec-Orion leadership team

Management profile

Number of profiles

Profiles14 records

Simbec-Orion subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Simbec-Orion funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Simbec-Orion M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Simbec-Orion

What does Simbec-Orion do?

Simbec-Orion is a full-service Contract Research Organisation (CRO) that manages clinical trials end-to-end for small and mid-sized biotech and pharmaceutical sponsors, covering Phase I (including First-in-Human, PK, food effect, and drug-drug interaction studies) through Phase III and post-market studies from its MHRA-accredited 58-bed Phase I Clinical Pharmacology Unit. It sells complementary services including central laboratory/bioanalytical testing, scintigraphy imaging, pharmacovigilance, regulatory affairs and submissions, clinical and medical writing, biometric services, site management and monitoring, IMP management, and SMO services, with deep specialization in oncology, rare and orphan diseases, respiratory, and CNS therapeutic areas.

Is Simbec-Orion a public or private company?

Simbec-Orion is a private company. It is classified as unknown and is currently operating.

When was Simbec-Orion founded?

Simbec-Orion was founded in 1976. It employs 251 to 500 people.

Where is Simbec-Orion based?

Simbec-Orion is headquartered in Merthyr Tydfil, United Kingdom, in the Europe region.

How does Simbec-Orion make money?

Eight revenue lines are on record. Clinical Trial Management Services are the primary driver. The others are clinical Pharmacology Services, central Laboratory Services, regulatory Affairs, clinical & Medical Writing, scintigraphy Services, pharmacovigilance and SMO Services.

Who are Simbec-Orion's main competitors?

Direct peers on record are Medpace Holdings, Worldwide Clinical Trials, Premier Research, Clinipace Worldwide and Avance Clinical. Broad incumbents are IQVIA, Charles River Laboratories, INC Research (Syneos Health legacy) and ICON plc. ERT (Clario) is listed as an others.

Does Simbec-Orion have an API?

No public API is recorded for Simbec-Orion.

What industry is Simbec-Orion in?

Simbec-Orion's product category is Clinical Research Services (Contract Research Organization). Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FierceBiotechCaidya and Simbec-Orion unite in global CRO comboContract research organizations Caidya and Simbec-Orion have merged to form a combined company operating under the Caidya name, creating a global platform spanning Europe, the Americas, Asia-Pacific, and China. North Carolina-based Caidya, launched in 2022 after rebranding from dMed-Clinipace and backed by a $165M investment from Rubicon Founders, brings global reach across 30+ countries, while London-based Simbec-Orion contributes early-phase development expertise in clinical pharmacology, oncology, and rare diseases with five decades of experience in Europe. The deal, with no price disclosed, is designed to expand Simbec-Orion's access to U.S. and Asian markets while deepening Caidya's European footprint and Phase 1 trial capabilities.IntelligenthealthCaidya expands European clinical research capabilities through Simbec-Orion strategic combination – Intelligent Health.techCaidya has announced a strategic combination with Simbec-Orion, creating a differentiated specialty clinical contract research organization (CRO) platform spanning early-phase studies through registration. The combined entity brings together Simbec-Orion's European presence, early-phase clinical pharmacology capabilities including a 48-bed Phase I unit, and therapeutic expertise in oncology and rare disease, with Caidya's global platform covering the Americas, APAC, and China. CBPE, a private equity firm that has backed Simbec-Orion since 2019, expressed confidence in the combination as the next chapter for the business.StartupriseCaidya Announces Strategic Combination with Simbec-OrionCaidya announced a strategic combination with Simbec-Orion to create a specialized clinical contract research organization (CRO) serving biopharma companies. The merged entity will have operations across Europe, the Americas, Asia-Pacific, and China, combining Simbec-Orion's early-stage clinical pharmacology capabilities and 48-bed Phase I unit with Caidya's global platform. The companies expect the combination to support drug developers from first-in-human studies through regulatory approval while offering broader services and deeper scientific expertise.InvestorsinhealthcareUK: Caidya announces strategic combination with Simbec-OrionCaidya, a global CRO, announced a strategic combination with UK-based CRO Simbec-Orion. The deal aims to close the divide between early scientific insight and global clinical execution. No further details were disclosed.Business Wire BlogCaidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical ExecutionCaidya, a global contract research organization (CRO), announced a strategic combination with Simbec-Orion, a UK-based CRO specializing in clinical pharmacology, oncology, and rare diseases, to create a differentiated specialty clinical CRO platform. The combined entity will operate across Europe, the Americas, APAC, and China, bringing together Simbec-Orion's early-phase clinical pharmacology capabilities and 48-bed Phase I unit with Caidya's global platform and therapeutic expertise. Under the deal, Caidya CEO Barbara Lopez Kunz will lead the combined organization, with Simbec-Orion CEO Fabrice Chartier continuing to oversee Simbec-Orion's operations as part of the merged company.FinancialContent Business PageCaidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical ExecutionCaidya announced a strategic combination with Simbec-Orion, merging two clinical research organizations to create a differentiated specialty CRO platform spanning Europe, the Americas, APAC, and China. The combined entity integrates Simbec-Orion's early-phase clinical pharmacology capabilities and 48-bed Phase I unit with Caidya's global platform to offer sponsors a continuous path from First-in-Human studies through registration. The new organization will operate under Caidya CEO Barbara Lopez Kunz, with Fabrice Chartier continuing to lead Simbec-Orion's operations as part of the combined company.CaidyaCaidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical ExecutionCaidya announced a strategic combination with Simbec-Orion to create a specialty clinical CRO platform. The combined organization will be led by Barbara Lopez Kunz as CEO, with Fabrice Chartier continuing to lead Simbec-Orion's operations. The merger aims to bridge early-phase clinical pharmacology with global clinical execution.citybizCaidya Combines With Simbec-Orion to Expand Global Clinical Research CapabilitiesCaidya announced a strategic combination with UK-based CRO Simbec-Orion, creating a global specialty clinical research platform. Financial terms were not disclosed. The combined company will operate under the Caidya brand, with Lopez Kunz as CEO and Chartier leading Simbec-Orion operations.SimbecorionCaidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical ExecutionCaidya announced a strategic combination with Simbec-Orion to create a specialty clinical CRO platform. The combined organization will be led by Barbara Lopez Kunz as CEO, with Fabrice Chartier continuing to lead Simbec-Orion's operations. The deal aims to expand geographic footprint and support cross-border biopharma development.